{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T04:30:27Z","timestamp":1794803427308,"version":"4.9.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["274993; 332727"],"award-info":[{"award-number":["274993; 332727"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["287927; 332727"],"award-info":[{"award-number":["287927; 332727"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["274993; 332727"],"award-info":[{"award-number":["274993; 332727"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["274993; 332727"],"award-info":[{"award-number":["274993; 332727"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["332727"],"award-info":[{"award-number":["332727"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Ministry of Health and Care Services | Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2024046"],"award-info":[{"award-number":["2024046"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"name":"M.F. T. was supported by the Access to Insight Basic Research Grant (Novo Nordisk) and by the Fondo di Ateneo per la Ricerca (FAR) from the University of Ferrara, Italy."},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["223315"],"award-info":[{"award-number":["223315"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"name":"F.B. was supported by the Access to Insight Basic Research Grant (Novo Nordisk) and by the Fondo di Ateneo per la Ricerca (FAR) from the University of Ferrara, Italy."},{"name":"M.P. was supported by the Access to Insight Basic Research Grant (Novo Nordisk) and by the Fondo di Ateneo per la Ricerca (FAR) from the University of Ferrara, Italy."},{"name":"A. B. was supported by the Access to Insight Basic Research Grant (Novo Nordisk) and by the Fondo di Ateneo per la Ricerca (FAR) from the University of Ferrara, Italy."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The efficacy of hemophilia B (HB) replacement therapy is evaluated by coagulation factor IX (FIX) activity in plasma, although FIX bound to extravascular type IV collagen (Col4) also contributes to efficient hemostasis. Here, we investigated the impact of engineering FIX for improved (K5R) or reduced (K5A) Col4 binding on the pharmacokinetic properties of FIX Padua, fused to human serum albumin (HSA\n                    <jats:sub>QMP<\/jats:sub>\n                    ) engineered for favorable neonatal Fc receptor (FcRn) engagement. Hyperactive features and extended plasma half-life in human FcRn expressing mice, attributed to FIX Padua and HSA\n                    <jats:sub>QMP<\/jats:sub>\n                    engineering, respectively, was confirmed. In HB mice, Padua\n                    <jats:sub>KA<\/jats:sub>\n                    -HSA\n                    <jats:sub>QMP<\/jats:sub>\n                    exhibited negligible extravascular distribution and the highest plasma levels at early time points followed by the steepest decay. Conversely, Padua\n                    <jats:sub>KR<\/jats:sub>\n                    -HSA\n                    <jats:sub>QMP<\/jats:sub>\n                    showed increased extravascular distribution and a 3-fold longer functional half-life (80\u2009hours). These findings support the use of Padua\n                    <jats:sub>KA<\/jats:sub>\n                    -HSA\n                    <jats:sub>QMP<\/jats:sub>\n                    and Padua\n                    <jats:sub>KR<\/jats:sub>\n                    -HSA\n                    <jats:sub>QMP<\/jats:sub>\n                    as hyperactive short- or long-term therapeutics, respectively, with opportunities for tailored HB replacement therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-62955-9","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T09:05:40Z","timestamp":1759136740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7181-1052","authenticated-orcid":false,"given":"Kristin Hovden","family":"Aaen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Nilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Canepari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mascia","family":"Benedusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-8125","authenticated-orcid":false,"given":"Sopisa","family":"Benjakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5248-6722","authenticated-orcid":false,"given":"Mari","family":"Nyquist-Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Leangen","family":"Herigstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9741-997X","authenticated-orcid":false,"given":"Alessio","family":"Cantore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Valacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Sandlie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Pinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6113-2694","authenticated-orcid":false,"given":"Alessio","family":"Branchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1710-1628","authenticated-orcid":false,"given":"Jan Terje","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"62955_CR1","doi-asserted-by":"publisher","first-page":"204062072210852","DOI":"10.1177\/20406207221085202","volume":"13","author":"DP Hart","year":"2022","unstructured":"Hart, D. P. et al. International consensus recommendations on the management of people with haemophilia B. Ther. Adv. Hematol. 13, 20406207221085202 (2022).","journal-title":"Ther. Adv. Hematol."},{"key":"62955_CR2","first-page":"33","volume":"35","author":"G White","year":"1998","unstructured":"White, G. et al. Clinical evaluation of recombinant factor IX. Semin. Hematol. 35, 33\u201338 (1998).","journal-title":"Semin. Hematol."},{"key":"62955_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1046\/j.1365-2516.2001.00465.x","volume":"7","author":"S Bj\u00f6rkman","year":"2001","unstructured":"Bj\u00f6rkman, S., Shapiro, A. D. & Berntorp, E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 7, 133\u2013139 (2001).","journal-title":"Haemophilia"},{"key":"62955_CR4","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1182\/blood-2011-02-336172","volume":"118","author":"H \u00d8stergaard","year":"2011","unstructured":"\u00d8stergaard, H. et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 118, 2333\u20132341 (2011).","journal-title":"Blood"},{"key":"62955_CR5","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","volume":"124","author":"PW Collins","year":"2014","unstructured":"Collins, P. W. et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood 124, 3880\u20133886 (2014).","journal-title":"Blood"},{"key":"62955_CR6","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1182\/blood-2009-08-239665","volume":"115","author":"RT Peters","year":"2010","unstructured":"Peters, R. T. et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 115, 2057\u20132064 (2010).","journal-title":"Blood"},{"key":"62955_CR7","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood-2011-07-367003","volume":"119","author":"AD Shapiro","year":"2012","unstructured":"Shapiro, A. D. et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1\/2a study in hemophilia B patients. Blood 119, 666\u2013672 (2012).","journal-title":"Blood"},{"key":"62955_CR8","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","volume":"369","author":"JS Powell","year":"2013","unstructured":"Powell, J. S. et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N. Engl. J. Med. 369, 2313\u20132323 (2013).","journal-title":"N. Engl. J. Med."},{"key":"62955_CR9","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1182\/bloodadvances.2020004085","volume":"5","author":"B Nolan","year":"2021","unstructured":"Nolan, B. et al. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Adv. 5, 2732\u20132739 (2021).","journal-title":"Blood Adv."},{"key":"62955_CR10","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1160\/TH09-04-0255","volume":"102","author":"HJ Metzner","year":"2009","unstructured":"Metzner, H. J., Weimer, T., Kronthaler, U., Lang, W. & Schulte, S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thrombosis Haemost. 102, 634\u2013644 (2009).","journal-title":"Thrombosis Haemost."},{"key":"62955_CR11","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1182\/blood-2012-05-429688","volume":"120","author":"E Santagostino","year":"2012","unstructured":"Santagostino, E. et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 120, 2405\u20132411 (2012).","journal-title":"Blood"},{"key":"62955_CR12","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","volume":"127","author":"E Santagostino","year":"2016","unstructured":"Santagostino, E. et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood 127, 1761\u20131769 (2016).","journal-title":"Blood"},{"key":"62955_CR13","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1182\/blood.V124.21.1491.1491","volume":"124","author":"E Santagostino","year":"2014","unstructured":"Santagostino, E., Jacobs, I. C., Voigt, C., Feussner, A. & Limsakun, T. Pharmacokinetic results of two phase III clinical studies of coagulation factor IX (recombinant) albumin fusion protein (rIX-FP) in previously treated patients with hemophilia B (PROLONG-9FP). Blood 124, 1491 (2014).","journal-title":"Blood"},{"key":"62955_CR14","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/S2352-3026(16)30193-4","volume":"4","author":"K Fischer","year":"2017","unstructured":"Fischer, K. et al. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol. 4, e75\u2013e82 (2017).","journal-title":"Lancet Haematol."},{"key":"62955_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1084\/jem.20021829","volume":"197","author":"C Chaudhury","year":"2003","unstructured":"Chaudhury, C. et al. The major histocompatibility complex\u2013related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med. 197, 315\u2013322 (2003).","journal-title":"J. Exp. Med."},{"key":"62955_CR16","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","volume":"170","author":"DC Roopenian","year":"2003","unstructured":"Roopenian, D. C. et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J. Immunol. 170, 3528\u20133533 (2003).","journal-title":"J. Immunol."},{"key":"62955_CR17","doi-asserted-by":"publisher","first-page":"11076","DOI":"10.1073\/pnas.0402970101","volume":"101","author":"RJ Ober","year":"2004","unstructured":"Ober, R. J., Martinez, C., Lai, X., Zhou, J. & Ward, E. S. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc. Natl Acad. Sci. USA 101, 11076\u201311081 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"62955_CR18","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1073\/pnas.0700337104","volume":"104","author":"P Prabhat","year":"2007","unstructured":"Prabhat, P. et al. Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Proc. Natl Acad. Sci. USA 104, 5889\u20135894 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"62955_CR19","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1242\/jcs.116327","volume":"126","author":"Z Gan","year":"2013","unstructured":"Gan, Z., Ram, S., Ober, R. J. & Ward, E. S. Using multifocal plane microscopy to reveal novel trafficking processes in the recycling pathway. J. cell Sci. 126, 1176\u20131188 (2013).","journal-title":"J. cell Sci."},{"key":"62955_CR20","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1074\/jbc.M117.817064","volume":"293","author":"J Chia","year":"2018","unstructured":"Chia, J. et al. Half-life\u2013extended recombinant coagulation factor IX\u2013albumin fusion protein is recycled via the FcRn-mediated pathway. J. Biol. Chem. 293, 6363\u20136373 (2018).","journal-title":"J. Biol. Chem."},{"key":"62955_CR21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1172\/JCI106279","volume":"49","author":"A Morell","year":"1970","unstructured":"Morell, A., Terry, W. D. & Waldmann, T. A. Metabolic properties of IgG subclasses in man. J. Clin. Investig. 49, 673\u2013680 (1970).","journal-title":"J. Clin. Investig."},{"key":"62955_CR22","doi-asserted-by":"crossref","unstructured":"Peters, Jr, T., Serum albumin. In Advances in protein chemistry (Elsevier, 1985). p. 161\u2013245.","DOI":"10.1016\/S0065-3233(08)60065-0"},{"key":"62955_CR23","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","volume":"361","author":"P Simioni","year":"2009","unstructured":"Simioni, P. et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N. Engl. J. Med. 361, 1671\u20131675 (2009).","journal-title":"N. Engl. J. Med."},{"key":"62955_CR24","doi-asserted-by":"publisher","first-page":"eabb0580","DOI":"10.1126\/scitranslmed.abb0580","volume":"12","author":"M Bern","year":"2020","unstructured":"Bern, M. et al. An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. Sci. Transl. Med. 12, eabb0580 (2020).","journal-title":"Sci. Transl. Med."},{"key":"62955_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjh.17559","volume":"194","author":"S Lombardi","year":"2021","unstructured":"Lombardi, S. et al. Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity. Br. J. Haematol. 194, 453\u2013462 (2021).","journal-title":"Br. J. Haematol."},{"key":"62955_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/0006-291X(83)90365-0","volume":"111","author":"RL Heimark","year":"1983","unstructured":"Heimark, R. L. & Schwartz, S. M. Binding of coagulation factors IX and X to the endothelial cell surface. Biochem. Biophys. Res. Commun. 111, 723\u2013731 (1983).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"62955_CR27","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1073\/pnas.80.13.4119","volume":"80","author":"DM Stern","year":"1983","unstructured":"Stern, D. M. et al. Binding of factors IX and IXa to cultured vascular endothelial cells. Proc. Natl Acad. Sci. USA 80, 4119\u20134123 (1983).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"62955_CR28","doi-asserted-by":"publisher","first-page":"6717","DOI":"10.1016\/S0021-9258(18)88838-X","volume":"260","author":"DM Stern","year":"1985","unstructured":"Stern, D. M., Nawroth, P., Kisiel, W., Vehar, G. & Esmon, C. T. The binding of factor IXa to cultured bovine aortic endothelial cells. Induction of a specific site in the presence of factors VIII and X. J. Biol. Chem. 260, 6717\u20136722 (1985).","journal-title":"J. Biol. Chem."},{"key":"62955_CR29","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.1016\/S0021-9258(18)45532-9","volume":"262","author":"S Rimon","year":"1987","unstructured":"Rimon, S. et al. Identification of a factor IX\/IXa binding protein on the endothelial cell surface. J. Biol. Chem. 262, 6023\u20136031 (1987).","journal-title":"J. Biol. Chem."},{"key":"62955_CR30","doi-asserted-by":"publisher","first-page":"20529","DOI":"10.1016\/S0021-9258(19)36713-4","volume":"267","author":"W Cheung","year":"1992","unstructured":"Cheung, W., Hamaguchi, N., Smith, K. & Stafford, D. The binding of human factor IX to endothelial cells is mediated by residues 3-11. J. Biol. Chem. 267, 20529\u201320531 (1992).","journal-title":"J. Biol. Chem."},{"key":"62955_CR31","doi-asserted-by":"publisher","first-page":"11068","DOI":"10.1073\/pnas.93.20.11068","volume":"93","author":"W-F Cheung","year":"1996","unstructured":"Cheung, W.-F. et al. Identification of the endothelial cell binding site for factor IX. Proc. Natl Acad. Sci. USA 93, 11068\u201311073 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"62955_CR32","doi-asserted-by":"publisher","first-page":"16717","DOI":"10.1074\/jbc.272.27.16717","volume":"272","author":"AS Wolberg","year":"1997","unstructured":"Wolberg, A. S., Stafford, D. W. & Erie, D. A. Human factor IX binds to specific sites on the collagenous domain of collagen IV. J. Biol. Chem. 272, 16717\u201316720 (1997).","journal-title":"J. Biol. Chem."},{"key":"62955_CR33","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1073\/pnas.94.11.5804","volume":"94","author":"RW Herzog","year":"1997","unstructured":"Herzog, R. W. et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl Acad. Sci. USA 94, 5804\u20135809 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"62955_CR34","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1172\/JCI111377","volume":"73","author":"H Fuchs","year":"1984","unstructured":"Fuchs, H., Trapp, H., Griffith, M., Roberts, H. & Pizzo, S. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors. J. Clin. Investig. 73, 1696\u20131703 (1984).","journal-title":"J. Clin. Investig."},{"key":"62955_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1182\/blood.V100.1.153","volume":"100","author":"T Gui","year":"2002","unstructured":"Gui, T. et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 100, 153\u2013158 (2002).","journal-title":"Blood"},{"key":"62955_CR36","unstructured":"Bri\u00ebt, E. Three problems of hemophilia B: a study of abnormal factor IX molecules with an inhibitor neutralization assay. [PhD thesis, Leiden University Medical Center, Netherlands] (1977)."},{"key":"62955_CR37","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1046\/j.1365-2516.2001.00494.x","volume":"7","author":"P Chowdary","year":"2001","unstructured":"Chowdary, P. et al. Recombinant factor IX (BeneFix\u00ae) by adjusted continuous infusion: a study of stability, sterility and clinical experience. Haemophilia 7, 140\u2013145 (2001).","journal-title":"Haemophilia"},{"key":"62955_CR38","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1182\/blood-2004-01-0138","volume":"104","author":"D-Y Jin","year":"2004","unstructured":"Jin, D.-Y., Zhang, T.-P., Gui, T., Stafford, D. W. & Monahan, P. E. Creation of a mouse expressing defective human factor IX. Blood 104, 1733\u20131739 (2004).","journal-title":"Blood"},{"key":"62955_CR39","first-page":"s21","volume":"6","author":"M Morfini","year":"2008","unstructured":"Morfini, M. Secondary prophylaxis with factor IX concentrates: continuous infusion. Blood Transfus. 6, s21 (2008).","journal-title":"Blood Transfus."},{"key":"62955_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2516.2010.02370.x","volume":"17","author":"PW Collins","year":"2011","unstructured":"Collins, P. W., Fischer, K., Morfini, M., Blanchette, V. S. & Bj\u00f6rkman, S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 17, 2\u201310 (2011).","journal-title":"Haemophilia"},{"key":"62955_CR41","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1111\/jth.12421","volume":"11","author":"D Feng","year":"2013","unstructured":"Feng, D., Stafford, K. A., Broze, G. J. & Stafford, D. W. Evidence of clinically significant extravascular stores of factor IX. J. Thrombosis Haemost. 11, 2176\u20132178 (2013).","journal-title":"J. Thrombosis Haemost."},{"key":"62955_CR42","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1182\/blood.2018884015","volume":"133","author":"B Cooley","year":"2019","unstructured":"Cooley, B. et al. Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model. Blood 133, 2445\u20132451 (2019).","journal-title":"Blood"},{"key":"62955_CR43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/jth.15552","volume":"20","author":"A Branchini","year":"2021","unstructured":"Branchini, A. et al. F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes. J. Thrombosis Haemost. 20, 69\u201381 (2021).","journal-title":"J. Thrombosis Haemost."},{"key":"62955_CR44","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1182\/blood-2016-01-696104","volume":"128","author":"B Cooley","year":"2016","unstructured":"Cooley, B. et al. Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice. Blood 128, 286\u2013292 (2016).","journal-title":"Blood"},{"key":"62955_CR45","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/hae.14300","volume":"27","author":"DM Mann","year":"2021","unstructured":"Mann, D. M., Stafford, K. A., Poon, M. C., Matino, D. & Stafford, D. W. The Function of extravascular coagulation factor IX in haemostasis. Haemophilia 27, 332\u2013339 (2021).","journal-title":"Haemophilia"},{"key":"62955_CR46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1365-2141.1987.tb01303.x","volume":"66","author":"DM Stern","year":"1987","unstructured":"Stern, D. M., Knitter, G., Kisiel, W. & Nawroth, P. P. In vivo evidence of intravascular binding sites for coagulation factor IX. Br. J. Haematol. 66, 227\u2013232 (1987).","journal-title":"Br. J. Haematol."},{"key":"62955_CR47","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1021\/bi00121a031","volume":"31","author":"JR Toomey","year":"1992","unstructured":"Toomey, J. R., Smith, K. J., Roberts, H. R. & Stafford, D. W. The endothelial cell binding determinant of human factor IX resides in the. gamma.-carboxyglutamic acid domain. Biochemistry 31, 1806\u20131808 (1992).","journal-title":"Biochemistry"},{"key":"62955_CR48","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1111\/j.1538-7836.2009.03591.x","volume":"7","author":"D Gailani","year":"2009","unstructured":"Gailani, D. Factor IX binding to collagen. J. Thrombosis Haemost. 7, 1840\u20131842 (2009).","journal-title":"J. Thrombosis Haemost."},{"key":"62955_CR49","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood-2004-08-2990","volume":"105","author":"J Schuettrumpf","year":"2005","unstructured":"Schuettrumpf, J. et al. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 105, 2316\u20132323 (2005).","journal-title":"Blood"},{"key":"62955_CR50","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1055\/a-2090-9739","volume":"123","author":"S Knoll Machado","year":"2023","unstructured":"Knoll Machado, S. et al. Modulation of extravascular binding of recombinant factor IX impacts duration of efficacy in mouse models. Thrombosis Haemost. 123, 751\u2013762 (2023).","journal-title":"Thrombosis Haemost."},{"key":"62955_CR51","first-page":"693","volume":"22","author":"C-H Chang","year":"2008","unstructured":"Chang, C.-H. et al. Biodistribution and pharmacokinetics of transgenic pig-produced recombinant human factor IX (rhFIX) in rats. vivo 22, 693\u2013697 (2008).","journal-title":"vivo"},{"key":"62955_CR52","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.thromres.2014.02.010","volume":"133","author":"E Herzog","year":"2014","unstructured":"Herzog, E. et al. Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats. Thrombosis Res. 133, 900\u2013907 (2014).","journal-title":"Thrombosis Res."},{"key":"62955_CR53","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1111\/jth.15069","volume":"18","author":"S Herrmann","year":"2020","unstructured":"Herrmann, S. et al. Tissue distribution of rIX\u2010FP after intravenous application to rodents. J. Thrombosis Haemost. 18, 3194\u20133202 (2020).","journal-title":"J. Thrombosis Haemost."},{"key":"62955_CR54","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1074\/jbc.M109.081828","volume":"285","author":"JT Andersen","year":"2010","unstructured":"Andersen, J. T., Daba, M. B., Berntzen, G., Michaelsen, T. E. & Sandlie, I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J. Biol. Chem. 285, 4826\u20134836 (2010).","journal-title":"J. Biol. Chem."},{"key":"62955_CR55","doi-asserted-by":"crossref","unstructured":"Nilsen, J. et al. Human and mouse albumin bind their respective neonatal Fc receptors differently. Sci. Rep. 8, 14648 (2018).","DOI":"10.1038\/s41598-018-32817-0"},{"key":"62955_CR56","doi-asserted-by":"publisher","first-page":"24277","DOI":"10.1074\/jbc.M113.463000","volume":"288","author":"JT Andersen","year":"2013","unstructured":"Andersen, J. T. et al. Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics. J. Biol. Chem. 288, 24277\u201324285 (2013).","journal-title":"J. Biol. Chem."},{"key":"62955_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03061-x","volume":"9","author":"A Grevys","year":"2018","unstructured":"Grevys, A. et al. A human endothelial cell-based recycling assay for screening of FcRn targeted molecules. Nat. Commun. 9, 621 (2018).","journal-title":"Nat. Commun."},{"key":"62955_CR58","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-1-60761-058-8_6","volume":"602","author":"DC Roopenian","year":"2010","unstructured":"Roopenian, D. C., Christianson, G. J. & Sproule, T. J. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol. Biol. 602, 93\u2013104 (2010).","journal-title":"Methods Mol. Biol."},{"key":"62955_CR59","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10928-017-9562-9","volume":"45","author":"I Hosseini","year":"2018","unstructured":"Hosseini, I. et al. gPKPDSim: a SimBiology(\u00ae)-based GUI application for PKPD modeling in drug development. J. Pharmacokinet. Pharmacodyn. 45, 259\u2013275 (2018).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"62955_CR60","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1182\/blood.V90.10.3962","volume":"90","author":"H-F Lin","year":"1997","unstructured":"Lin, H.-F., Maeda, N., Smithies, O., Straight, D. L. & Stafford, D. W. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 90, 3962\u20133966 (1997).","journal-title":"Blood"},{"key":"62955_CR61","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/jcm11041071","volume":"11","author":"M Escobar","year":"2022","unstructured":"Escobar, M. et al. IDELVION: a comprehensive review of clinical trial and real-world data. J. Clin. Med. 11, 1071 (2022).","journal-title":"J. Clin. Med."},{"key":"62955_CR62","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/hae.13834","volume":"25","author":"F Peyvandi","year":"2019","unstructured":"Peyvandi, F. et al. Real\u2010life experience in switching to new extended half\u2010life products at European haemophilia centres. Haemophilia 25, 946\u2013952 (2019).","journal-title":"Haemophilia"},{"key":"62955_CR63","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1182\/blood-2018-99-114905","volume":"132","author":"LM Aledort","year":"2018","unstructured":"Aledort, L. M. et al. Changing the paradigm in hemophilia care: extended half-life products (rFVIIIFc and rFIXFc). Blood 132, 3514\u20133514 (2018).","journal-title":"Blood"},{"key":"62955_CR64","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/ajh.25844","volume":"95","author":"LM Malec","year":"2020","unstructured":"Malec, L. M. et al. The impact of extended half\u2010life factor concentrates on prophylaxis for severe hemophilia in the United States. Am. J. Hematol. 95, 960\u2013965 (2020).","journal-title":"Am. J. Hematol."},{"key":"62955_CR65","doi-asserted-by":"publisher","first-page":"1893888","DOI":"10.1080\/19420862.2021.1893888","volume":"13","author":"S Mester","year":"2021","unstructured":"Mester, S. et al. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo. MAbs 13, 1893888 (2021).","journal-title":"MAbs"},{"key":"62955_CR66","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.coisb.2020.10.010","volume":"24","author":"V Greiff","year":"2020","unstructured":"Greiff, V., Yaari, G. & Cowell, L. G. Mining adaptive immune receptor repertoires for biological and clinical information using machine learning. Curr. Opin. Syst. Biol. 24, 109\u2013119 (2020).","journal-title":"Curr. Opin. Syst. Biol."},{"key":"62955_CR67","doi-asserted-by":"publisher","first-page":"13492","DOI":"10.1074\/jbc.M114.549832","volume":"289","author":"JT Andersen","year":"2014","unstructured":"Andersen, J. T. et al. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. J. Biol. Chem. 289, 13492\u201313502 (2014).","journal-title":"J. Biol. Chem."},{"key":"62955_CR68","unstructured":"European Association for Haemophilia and Allied Disorders (EAHAD). Factor IX gene (F9) variant database (2022) https:\/\/f9-db.eahad.org\/index.php."},{"key":"62955_CR69","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/jth.12276","volume":"11","author":"P Rallapalli","year":"2013","unstructured":"Rallapalli, P., Kemball\u2010Cook, G., Tuddenham, E., Gomez, K. & Perkins, S. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J. Thrombosis Haemost. 11, 1329\u20131340 (2013).","journal-title":"J. Thrombosis Haemost."},{"key":"62955_CR70","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/blood-2016-05-713040","volume":"128","author":"P Lollar","year":"2016","unstructured":"Lollar, P. Fill\u2019er up? Fill what up? Blood 128, 156\u2013157 (2016).","journal-title":"Blood"},{"key":"62955_CR71","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/0161-5890(96)00004-1","volume":"33","author":"S Popov","year":"1996","unstructured":"Popov, S. et al. The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn. Mol. Immunol. 33, 521\u2013530 (1996).","journal-title":"Mol. Immunol."},{"key":"62955_CR72","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.4049\/jimmunol.1401218","volume":"194","author":"A Grevys","year":"2015","unstructured":"Grevys, A. et al. Fc engineering of human IgG1 for altered binding to the neonatal Fc receptor affects Fc effector functions. J. Immunol. 194, 5497\u20135508 (2015).","journal-title":"J. Immunol."},{"key":"62955_CR73","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/intimm\/13.8.993","volume":"13","author":"M Firan","year":"2001","unstructured":"Firan, M. et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of \u03b3-globulin in humans. Int. Immunol. 13, 993\u20131002 (2001).","journal-title":"Int. Immunol."},{"key":"62955_CR74","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1016\/j.jtha.2024.07.008","volume":"22","author":"M Sacco","year":"2024","unstructured":"Sacco, M. et al. An integrated multitool analysis contributes elements to interpreting unclassified factor IX missense variants associated with hemophilia B. J. Thrombosis Haemost. 22, 2724\u20132738 (2024).","journal-title":"J. Thrombosis Haemost."},{"key":"62955_CR75","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/nbt1143","volume":"23","author":"C Vaccaro","year":"2005","unstructured":"Vaccaro, C., Zhou, J., Ober, R. J. & Ward, E. S. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol. 23, 1283\u20131288 (2005).","journal-title":"Nat. Biotechnol."},{"key":"62955_CR76","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1091\/mbc.e13-04-0174","volume":"24","author":"AW Weflen","year":"2013","unstructured":"Weflen, A. W. et al. Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules. Mol. Biol. Cell 24, 2398\u20132405 (2013).","journal-title":"Mol. Biol. Cell"},{"key":"62955_CR77","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1016\/j.febslet.2013.08.019","volume":"587","author":"A Branchini","year":"2013","unstructured":"Branchini, A. et al. Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity. FEBS Lett. 587, 3249\u20133253 (2013).","journal-title":"FEBS Lett."},{"key":"62955_CR78","doi-asserted-by":"crossref","unstructured":"Cantore, A. et al. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood, 120, 4517\u20134520 (2012).","DOI":"10.1182\/blood-2012-05-432591"},{"key":"62955_CR79","unstructured":"Hosseini, I. gPKPDSimToolbox, https:\/\/github.com\/simkaryote\/gPKPDSim\/releases\/tag\/v1.1.3 (2022)."},{"key":"62955_CR80","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449\u2013W454 (2020).","journal-title":"Nucleic Acids Res."},{"key":"62955_CR81","doi-asserted-by":"publisher","first-page":"W24","DOI":"10.1093\/nar\/gkx346","volume":"45","author":"MC Jespersen","year":"2017","unstructured":"Jespersen, M. C., Peters, B., Nielsen, M. & Marcatili, P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 45, W24\u2013W29 (2017).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62955-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62955-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62955-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T09:05:47Z","timestamp":1759136747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62955-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62955"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62955-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"16 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.T.A. and I.S. are co\u2010inventors of patents, which are entitled \u201cAlbumin Variants and uses thereof\u201d (e.g. EP3063171B1, US10208102 and US10781245) and relate to the data described in this paper. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8433"}}